Brain Neurotherapy Bio, Inc.

Quick facts

Phase 2 pipeline

• AAV2-GDNF gene therapy · Neurology
  AAV2-GDNF gene therapy delivers a viral vector carrying the GDNF gene to the brain, where it is expressed and promotes the survival and growth of dopaminergic neurons.

Phase 1 pipeline

• AAV2-GDNF · Neurology
  AAV2-mediated delivery of glial cell line-derived neurotrophic factor

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Brain Neurotherapy Bio, Inc. portfolio CI brief
• Brain Neurotherapy Bio, Inc. pipeline updates RSS